Similar articles

• [Antibody-conjugated cytostatic drugs. Uses of monoclonal antibodies for new strategies in tumor therapy].

  Renner C, Pfreundschuh M. Renner C, et al. Fortschr Med. 1994 Oct 20;112(29):399. Fortschr Med. 1994. PMID: 8001887 German. No abstract available.
• Monoclonal antibodies. Targeted treatment.

  [No authors listed] [No authors listed] Mayo Clin Health Lett. 2003 Mar;21(3):1-3. Mayo Clin Health Lett. 2003. PMID: 12703461 No abstract available.
• Antibody drug conjugates - Trojan horses in the war on cancer.

  Iyer U, Kadambi VJ. Iyer U, et al. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):207-12. doi: 10.1016/j.vascn.2011.07.005. Epub 2011 Aug 6. J Pharmacol Toxicol Methods. 2011. PMID: 21843648 Review.
• [Antibodies as specific tumor therapy agents. Wishful thinking or reality?].

  Gramatzki M, Valerius T. Gramatzki M, et al. Internist (Berl). 1997 Nov;38(11):1055-62. doi: 10.1007/s001080050117. Internist (Berl). 1997. PMID: 9453954 Review. German. No abstract available.
• Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

  Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC Jr. Boyer CM, et al. Int J Cancer. 1999 Aug 12;82(4):525-31. doi: 10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j. Int J Cancer. 1999. PMID: 10404066